alimera
sciences
announces
multiple
posters
papers
highlighting
durability
presented
euretina
virtual
congress
nasdaq
alim
atlanta
globe
newswire
alimera
sciences
nasdaq
alim
alimera
leader
commercialization
development
prescription
ophthalmology
treatments
management
retinal
diseases
announces
clinical
data
fluocinolone
acetonide
intravitreal
implant
featured
papers
presentations
euretina
virtual
congress
held
october
key
presentations
include
data
supporting
safety
efficacy
iluvien
durable
continuous
delivery
system
treatment
diabetic
macular
edema
prevention
relapse
uveitis
affecting
posterior
segment
select
iluvien
papers
include
title
outcomes
european
registry
safety
study
observational
data
patients
dme
treated
fac
implant
clinical
practice
author
ramin
khoramnia
associate
professor
department
ophthalmology
university
heidelberg
heidelberg
germany
title
treated
fac
implant
fellow
eye
subgroup
analysis
study
author
carlos
pavesio
consultant
ophthalmologist
moorfields
eye
hospital
uk
title
uk
outcomes
patients
treated
mg
fac
implant
dme
medisoft
audit
group
author
claire
bailey
consultant
ophthalmologist
bristol
eye
hospital
uk
iluvien
alimera
primary
product
iluvien
fluocinolone
acetonide
intravitreal
implant
mg
sustained
release
intravitreal
implant
injected
back
eye
continuous
technology
iluvien
designed
release
levels
fluocinolone
acetonide
corticosteroid
months
reduce
recurrence
disease
enabling
patients
maintain
vision
longer
fewer
injections
iluvien
approved
canada
kuwait
lebanon
treat
diabetic
macular
edema
dme
patients
previously
treated
course
corticosteroids
clinically
significant
rise
intraocular
pressure
european
countries
iluvien
indicated
treatment
vision
impairment
associated
chronic
dme
considered
insufficiently
responsive
available
therapies
march
iluvien
received
approval
countries
mutual
recognition
procedure
prevention
relapse
recurrent
uveitis
affecting
posterior
segment
eye
countries
include
germany
france
italy
spain
portugal
ireland
austria
belgium
denmark
norway
finland
sweden
poland
czech
republic
netherlands
luxembourg
posterior
uveitis
indication
iluvien
launched
germany
iluvien
approved
treatment
uveitis
united
states
diabetic
macular
edema
dme
dme
primary
cause
vision
loss
associated
diabetic
retinopathy
disease
affecting
macula
part
retina
responsible
central
vision
blood
vessel
leakage
associated
diabetic
retinopathy
results
swelling
macula
condition
called
dme
onset
dme
painless
may
go
unreported
patient
manifests
blurring
central
vision
acute
vision
loss
severity
blurring
may
range
mild
profound
loss
vision
wisconsin
epidemiologic
study
diabetic
retinopathy
found
period
approximately
people
diabetes
included
study
diagnosed
dme
people
type
type
diabetes
risk
developing
dme
posterior
uveitis
nipu
posterior
segment
uveitis
chronic
inflammatory
disease
affecting
posterior
segment
eye
often
involving
retina
leading
cause
blindness
developed
developing
countries
affects
people
ages
producing
swelling
destroying
eye
tissues
lead
severe
vision
loss
blindness
patients
nipu
typically
treated
systemic
steroids
effective
time
frequently
lead
serious
side
effects
ranging
acne
weight
gain
sleep
mood
disorders
hypertension
osteoporosis
limit
effective
dosing
patients
often
progress
therapy
systemic
immune
suppressants
biologics
also
severe
side
effects
including
increased
risk
cancer
infection
result
remains
significant
need
new
therapies
improved
efficacy
tolerability
safety
profiles
manage
disease
alimera
sciences
alimera
sciences
pharmaceutical
company
specializes
commercialization
development
prescription
ophthalmic
pharmaceuticals
alimera
presently
focused
diseases
affecting
back
eye
retina
diseases
well
treated
current
therapies
affect
millions
people
aging
populations
information
please
visit
